
























Takeda Oncology Pipeline

Beginning with patients' needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate innovation. Our oncology R&D activities are focused on translating science into curative or transformative potential treatments by targeting tumor vulnerabilities and through novel strategies that leverage the power of innate immunity.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

INVESTIGATIONAL THERAPY	PLATFORM	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
Brigatinib*	Targeted therapy	2L ALK+ non-small cell lung cancer (GL)	Phase 3 	ALK inhibitor
		1L & 2L ALK+ non-small cell lung cancer (CN)	Filed 	
Cabozantinib*	Targeted therapy	Metastatic castration-resistant prostate cancer (JP)	Phase 3 	Tyrosine kinase inhibitor including MET/AXL/VEGFR Cabozantinib is being developed in Japan in collaboration with Exelixis.
		2L metastatic non-small cell lung cancer (JP)	Phase 3 	
Ixazomib*	Proteasome inhibitor	Maint. newly diagnosed multiple myeloma post-stem cell transplant (US, EU)	Phase 3 	Proteasome inhibitor
		Maint. newly diagnosed multiple myeloma without stem cell transplant (US, EU, CN)	Phase 3 	
Mobocertinib	Targeted therapy	2L EGFR Exon20 insertion non-small cell lung cancer (EU, CN)	Filed 	Oral EGFR Exon20 tyrosine kinase inhibitor
		1L EGFR Exon20 insertion non-small cell lung cancer (US, EU, GEM)	Phase 3 	
Ponatinib*	Targeted therapy	FL Ph+ acute lymphocytic leukemia (US)	Phase 3 	BCR-ABL inhibitor Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories).
Relugolix* (TAK-385)	Small molecule	Prostate cancer (JP, Asian countries)	Phase 3 	GnRH antagonist Relugolix is being developed in Japan and Asian countries in collaboration with Myovant Sciences, Inc.
Pevedinistat (TAK-924)	Targeted therapy	Acute myeloid leukemia	Phase 2** 	NEDD8-activating enzyme inhibitor **This trial is not registration-enabling.

INVESTIGATIONAL THERAPY	PLATFORM	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
TAK-007	I-O redirected immunity	<i>B-cell malignancies</i>	Phase 1/2 	CD19 CAR NK TAK-007 is being developed in collaboration with The University of Texas MD Anderson Cancer Center.
TAK-186	I-O redirected immunity	<i>EGFR-expressing solid tumors</i>	Phase 1/2 	EGFR x CD3 COBRA™ molecule (conditionally active bispecific T-cell engager immunotherapy)
TAK-573	I-O cold-to-hot	<i>Multiple myeloma</i>	Phase 1/2 	Anti-CD38 Attenukine™ TAK-573 was licensed from Teva Pharmaceuticals. Attenukine is a trademark of Teva Pharmaceutical Industries Ltd.
		<i>Solid tumors</i>	Phase 1/2 	
TAK-605	I-O cold-to-hot	<i>Solid tumors</i>	Phase 1/2 	Armored oncolytic virus TAK-605 is being developed in collaboration with Turnstone Biologics.
TAK-981	I-O cold-to-hot	<i>Non-Hodgkin lymphoma</i>	Phase 1/2 	SUMOylation inhibitor
		<i>Multiple myeloma</i>	Phase 1/2 	
		<i>Solid tumors</i>	Phase 1/2 	
TAK-102	I-O redirected immunity	<i>Solid tumors</i>	Phase 1 	GPC3 CAR-T TAK-102 is being developed in collaboration with Noile-Immune Biotech.
TAK-252	I-O cold-to-hot	<i>Solid tumors</i>	Phase 1 	Bifunctional checkpoint modulator TAK-252 is being developed in collaboration with Shattuck Labs.
TAK-676	I-O cold-to-hot	<i>Solid tumors</i>	Phase 1 	IV STING agonist
TAK-940	I-O redirected immunity	<i>B-cell malignancies</i>	Phase 1 	CD19-1XX CAR-T TAK-940 is being developed in collaboration with Memorial Sloan Kettering Cancer Center.

*Marketed products have received approval in one or more jurisdictions.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets

Learn more at [takedaoncology.com](https://www.takedaoncology.com)

 @TakedaOncology

©2021 Millennium Pharmaceuticals, Inc. All rights reserved.



ONCOLOGY